The FDA scheduled an advisory committee meeting for September to review Grail’s controversial cancer test after it failed to meet the primary endpoint in a large randomized UK trial. The agency’s move keeps the issue in the spotlight after earlier controversies around the test’s evidentiary basis and regulatory pathway. The advisory meeting signals the FDA’s continued scrutiny of clinical performance claims for early cancer detection assays and how benefits should be weighed against real-world implementation constraints. Industry watchpoints include how the committee frames endpoint selection, trial design sensitivity, and the level of evidence required for continued approvals or limiting restrictions.